221 related articles for article (PubMed ID: 36459489)
1. JAK/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells.
Fernández S; Solórzano JL; Díaz E; Menéndez V; Maestre L; Palacios S; López M; Colmenero A; Estévez M; Montalbán C; Martínez Á; Roncador G; García JF
Blood Adv; 2023 Aug; 7(15):4135-4147. PubMed ID: 36459489
[TBL] [Abstract][Full Text] [Related]
2. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Zahn M; Marienfeld R; Melzner I; Heinrich J; Renner B; Wegener S; Mießner A; Barth TF; Dorsch K; Brüderlein S; Möller P
Blood; 2017 Mar; 129(11):1480-1490. PubMed ID: 28082443
[TBL] [Abstract][Full Text] [Related]
3. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
4. The PTP1B mutant PTP1B∆2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Zahn M; Kaluszniak B; Möller P; Marienfeld R
Carcinogenesis; 2021 Apr; 42(4):517-527. PubMed ID: 33382412
[TBL] [Abstract][Full Text] [Related]
5. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E; Ladewig E; Schiavoni G; Penson A; Fortini E; Pettirossi V; Wang Y; Rosseto A; Venanzi A; Vlasevska S; Pacini R; Piattoni S; Tabarrini A; Pucciarini A; Bigerna B; Santi A; Gianni AM; Viviani S; Cabras A; Ascani S; Crescenzi B; Mecucci C; Pasqualucci L; Rabadan R; Falini B
Blood; 2018 May; 131(22):2454-2465. PubMed ID: 29650799
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma.
Schmitz R; Stanelle J; Hansmann ML; Küppers R
Annu Rev Pathol; 2009; 4():151-74. PubMed ID: 19400691
[TBL] [Abstract][Full Text] [Related]
7. Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
von Hoff L; Kärgel E; Franke V; McShane E; Schulz-Beiss KW; Patone G; Schleussner N; Kolesnichenko M; Hübner N; Daumke O; Selbach M; Akalin A; Mathas S; Scheidereit C
Blood; 2019 Mar; 133(13):1489-1494. PubMed ID: 30696620
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin lymphoma: Pathology and biology.
Mathas S; Hartmann S; Küppers R
Semin Hematol; 2016 Jul; 53(3):139-47. PubMed ID: 27496304
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Skinnider BF; Elia AJ; Gascoyne RD; Patterson B; Trumper L; Kapp U; Mak TW
Blood; 2002 Jan; 99(2):618-26. PubMed ID: 11781246
[TBL] [Abstract][Full Text] [Related]
11. Increased STAT expression in Reed-Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma.
Zargari A; Cummins KD; Hosking P; Pham A; Hawkes E; Ting SB
Pathology; 2023 Aug; 55(5):650-655. PubMed ID: 37169648
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
13. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
14. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer.
Yunianto I; Currie M; Chitcholtan K; Sykes P
J Obstet Gynaecol Res; 2023 Nov; 49(11):2563-2574. PubMed ID: 37565583
[TBL] [Abstract][Full Text] [Related]
15. The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension.
Roger I; Milara J; Montero P; Cortijo J
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067108
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
[TBL] [Abstract][Full Text] [Related]
17. Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With "Hodgkin/Reed-Sternberg-like" Cells of NK Phenotype.
Chen Z; Liu W; Zhang W; Ye Y; Guan P; Gao L; Zhao S
Am J Surg Pathol; 2019 Dec; 43(12):1611-1621. PubMed ID: 31305266
[TBL] [Abstract][Full Text] [Related]
18. BET inhibitors induce NF-κB and E2F downregulation in Hodgkin and Reed-Sternberg cells.
Fernández S; Díaz E; Rita CG; Estévez M; Montalbán C; García JF
Exp Cell Res; 2023 Sep; 430(2):113718. PubMed ID: 37468057
[TBL] [Abstract][Full Text] [Related]
19. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
20. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
